MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma
Oncotarget2015Vol. 7(1), pp. 266–278
Citations Over TimeTop 10% of 2015 papers
Chendan Zou, Weiming Zhao, Xiaona Wang, Qiang Li, Hui Huang, Wanpeng Cheng, Jianfeng Jin, He Zhang, Mingjuan Wu, Sheng Tai, Chaoxia Zou, Xu Gao
Abstract
MicroRNAs (miRNAs) are dysregulated in many types of malignancies, including human hepatocellular carcinoma (HCC). MiR-107 has been implicated in several types of cancer regulation; however, relatively little is known about miR-107 in human HCC. In the present study, we showed that the overexpression of miR-107 accelerates the tumor progression of HCC in vitro and in vivo through its new target gene, CPEB3. Furthermore, our results demonstrated that CPEB3 is a newly discovered tumor suppressor that acts via the EGFR pathway. Therefore, our study demonstrates that the newly discovered miR-107/CPEB3/EGFR axis plays an important role in HCC progression and might represent a new potential therapeutic target for HCC treatment.
Related Papers
- Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.(2003)
- Spontaneous rupture of hepatocellular carcinoma.(2002)
- Pathology of hepatocellular carcinoma(2006)
- The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west.(1997)
- Analysis of the influence factors of serum alpha-fetoprotein levels in patients with hepatocellular carcinoma(2001)